Abstract
IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8+ T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.
Funding Information
  • NIH (R01 CA198533 and R01CA201246)
  • Breast Cancer Research Foundation
  • Spanish Breast Cancer Group